产品简要
公司名称 :
赛默飞世尔
其他品牌 :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
产品类型 :
抗体
产品名称 :
CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), eBioscience™
目录 :
14-9908-82
规格 :
100微克
价格 :
美国248
克隆性 :
单克隆
宿主 :
小鼠
共轭标签 :
未共轭
克隆名称 :
DJR2-4(7-8)
反应物种 :
人类
应用 :
免疫细胞化学, 流式细胞仪
更多信息或购买 :
文章摘录数: 32
出版应用/物种/样本/稀释 | 参考文献 |
---|---|
| |
Woldemichael G, Turbyville T, Vasselli J, Linehan W, McMahon J. Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A. Neoplasia. 2012;14:771-7 pubmed
| |
Verbrugge I, de Vries E, Tait S, Wissink E, Walczak H, Verheij M, et al. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene. 2008;27:574-84 pubmed
| |
Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri F, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007;67:4981-8 pubmed
| |
Vanoosten R, Earel J, Griffith T. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis. 2007;12:561-71 pubmed
| |
Zou W, Liu X, Yue P, Khuri F, Sun S. PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther. 2007;6:99-106 pubmed
| |
Mattarollo S, Kenna T, Nieda M, Nicol A. Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V alpha 24+ NKT cell-mediated cytotoxicity. Int J Cancer. 2006;119:1630-7 pubmed
| |
VanOosten R, Earel J, Griffith T. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther. 2006;13:628-32 pubmed
| |
Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology. 2006;43:362-72 pubmed
| |
Earel J, Vanoosten R, Griffith T. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 2006;66:499-507 pubmed
|
产品信息
产品类型 :
抗体
产品名称 :
CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), eBioscience™
目录# :
14-9908-82
规格 :
100微克
价格 :
美国248
克隆性 :
单克隆
纯度 :
亲和色谱
宿主 :
小鼠
反应物种 :
人类
应用 :
Flow Cytometry: 1 µg/test, Immunocytochemistry: 5 µg/mL, Immunofluorescence: 5 µg/mL
物种 :
人类
克隆 :
DJR2-4(7-8)
抗体亚型 :
IgG1, kappa
储存 :
4° C
描述 :
DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.
格式 :
液体
应用w/稀释 :
Flow Cytometry: 1 µg/test, Immunocytochemistry: 5 µg/mL, Immunofluorescence: 5 µg/mL
别名 :
apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; DR5; dr-5; Fas-like protein; Killer; KILLER/DR5; KILLER/DR5 TRAIL death-inducing receptor; Ly98; MK; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF receptor superfamily member 10b; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; UNQ160/PRO186; ZTNFR9
更多信息或购买 :
公司信息
赛默飞世尔
产品浏览
- CD262 (DR5) Monoclonal Antibody (DJR2-2 (2-6)), eBioscience™ | 14-9909-80
- CD262 (DR5) Monoclonal Antibody (DJR2-2 (2-6)), eBioscience™ | 14-9909-82
- PCNA Monoclonal Antibody (PC10 (3F81)), eBioscience™ | 14-9910-80
- PCNA Monoclonal Antibody (PC10 (3F81)), eBioscience™ | 14-9910-82
- CD281 (TLR1) Monoclonal Antibody (GD2.F4), eBioscience™ | 14-9911-80
问题和意见